associated with reduced odds of A(H1N1)pdm09 infection in 2015-2016. 48 Conclusions: Serum collected after hospital admission can be used to assess correlates of protection 49 against influenza infection. Broader implementation of similar studies would provide an opportunity to 50 understand the successes and shortcomings of current influenza vaccines. 51
Influenza infections are responsible for substantial numbers of hospitalizations and deaths each year [1] . 52 Therefore, in the US, all individuals ≥6 months of age are recommended to receive annual influenza 53 vaccination to prevent clinical influenza and the severe complications associated with influenza illness 54 [2] . Continuous evolution of the influenza virus necessitates annual assessment of the strains composing 55 influenza vaccines with vaccine strain selection occurring well in advance of the subsequent influenza 56 season [3] . Because influenza vaccine effectiveness (VE) can vary, particularly by the antigenic match 57 between vaccine strain and circulating epidemic viruses, annual VE assessments are necessary to inform 58 policy makers, health care providers, and the public of the effectiveness of the influenza vaccine. 59
As a result, influenza VE is now evaluated annually in many countries with the majority of studies carried 60 out in outpatient settings [4] [5] [6] . A number of issues with current influenza vaccines have now become 61 clear, many of which are influenza type and subtype specific. On average, influenza vaccines have been 62 only approximately 30% effective in preventing influenza A(H3N2) infection, and were ineffective in 63 preventing antigenically drifted viruses during the 2014-2015 season [7] [8] [9] . Reasons for low VE against 64 A(H3N2) are not completely understood, but given consistently lower VE, it is likely that factors 65 contribute in addition to antigenic match between the hemagglutinin of vaccine and circulating viruses 66 [10] . A potentially related issue is that reduced VE has been frequently demonstrated among individuals 67 vaccinated in consecutive seasons compared to those vaccinated only in the current season [11] . 68
Immunologic evaluations are needed to help explain the factors underlying low VE, improve vaccine 69 strain selection, and guide novel vaccine development [12] . Unfortunately, in outpatient settings, it is 70 difficult to integrate immunologic evaluations because subject participation is generally limited to a 71 short interaction during acute illness. VE studies are increasingly being carried out among inpatient 72 populations [13] [14] [15] [16] . Hospitalized patients regularly have blood collected at hospital admission for 73 clinical purposes that could be used to support VE estimates from hospital-based studies. It is unclear 74 how well antibody titers measured in these specimens reflect pre-infection immune status, because the 75 antibody response to infection can begin within days of illness onset. 76
In this study we aimed to determine if antibody titers measured in serum specimens collected from 77 hospitalized patients during acute influenza illness accurately reflect pre-infection humoral immunity, 78 and if so, to determine how well influenza vaccine specific antibodies correlated with odds of infection. 79
The study was performed during the 2014-2015 and 2015-2016 influenza seasons. These two seasons 80 differed in the predominant circulating strains and the resulting VE estimates. In 2014-15, a drifted 81 influenza A(H3N2) virus belonging to the 3C.2a genetic group predominated in the United States [9] . The 82 vaccine was ineffective in ambulatory populations against drifted viruses, but moderately effective 83 against other circulating genetic groups that were more closely related to the vaccine virus [9] . In 84 contrast, we estimated modest, but statistically significant VE against influenza A(H3N2) in this 85 hospitalized population [13] . The following year, 2015-2016, influenza A(H1N1)pdm09 viruses 86 predominated, and VE was 45% against influenza A(H1N1)pdm09 in the ambulatory setting [17] . 87
METHODS 88
During the 2014-2015 and 2015-2016 influenza seasons adult (≥18 years) patients hospitalized for 89 treatment of acute respiratory illnesses at the University of Michigan Hospital in Ann Arbor and the 90 Henry Ford (HF) Hospital in Detroit were prospectively enrolled in a case-test negative design study of 91 influenza vaccine effectiveness as previously described [13] . All patients were enrolled ≤10 days from 92 illness onset during the period of influenza circulation each year (November-March 2014-2015; January-93 April 2015-2016). Participants completed an enrollment interview and had throat and nasal swab 94 specimens collected and combined for influenza identification. When available, clinical serum specimens 95 collected as early as possible after hospital admission were retrieved; all specimens were collected ≤10 96 days from illness onset based on the enrollment case definition. Serum specimens were available only 97 for patients enrolled from University of Michigan Hospital during the 2014-2015 season, but were 98 available for patients enrolled from both hospitals during the 2015-2016 season. The institutional 99 review boards at both participating health systems reviewed and approved the study. 100
Participant Data 101
Enrolled patients were interviewed to collect information on demographic characteristics (age, sex, 102 race/ethnicity), illness onset date, self-reported influenza vaccination status, and frailty (instrument fully 103 described in Supplement). Health System Electronic Medical Records were reviewed to document 104 evidence of health conditions present during the year before enrollment to calculate the Charlson 105 comorbidity index. Influenza vaccination in each season was based on documented evidence of vaccine 106 receipt from the Electronic Medical Record or statewide immunization registry or from self-report of 107 vaccine receipt at enrollment with plausible location and timing of vaccination (plausible self-report). 108
Laboratory Assays 109
Respiratory specimens were tested for influenza by RT-PCR in the investigators' laboratory at the respectively, and a mismatched HA (H6 subtype) to avoid interference by HA-specific antibodies [18] . 125
Serologic testing was performed in the investigators' laboratory at the University of Michigan School of 126
Public Health (methods for each assay are fully described in Supplement). 127
Statistical Analysis 128
Subjects were characterized by demographics, health status, influenza vaccination status, and influenza 129 infection status. HAI and NAI titers were calculated as the reciprocal (e.g., 40) of the highest dilution of 130 sera (e.g., 1:40) that inhibited HA or NA activity. Titers were log-base 2 transformed, and the mean of 131 the transformed values was calculated and then exponentiated to obtain the geometric mean titer 132 (GMT). GMTs were compared by subject characteristics including health, current and prior vaccination, 133 and infection status using unbalanced ANOVA F-tests or Wilcoxon Rank Sum tests. 134
To evaluate the assumption that antibody titers measured in specimens during acute illness reflect pre-135 infection titers rather than a de novo response to infection, we estimated the association between log-136 base-2 antibody titer and days from illness onset to specimen collection among individuals with 137 laboratory-confirmed influenza infection using linear regression models. If measured antibody titers 138 reflect a de novo response, those collected later in the illness would be expected to have higher 139 antibody titers, which would be reflected in a positive slope estimated by the regression. Similarly, we 140 evaluated the possibility that influenza negative controls, particularly those enrolled later in the season, 141 could have been infected before the time of enrollment. This was accomplished by estimating the 6 association between log-base-2 antibody titer and day of illness onset within each season among 143 influenza negative controls using linear regression models. If a substantial proportion of control subjects 144 were infected at some time prior to enrollment, those enrolled later in the season would be expected to 145 have higher antibody titers, which would be reflected in a positive slope estimated by the regression. 146
We estimated the change in odds of influenza infection (Odds Ratio [OR]) associated with a 2-fold 147 increase in preseason HAI and NAI titers modeled as continuous, log-base 2 transformed predictors in 148 logistic regression models for each influenza season. We specified models to assess the effect of each 149 titer individually, to assess the independent effect of each titer holding other measured titers constant 150 (partial adjustment), and to assess the effect of each titer after adjustment for other measured titers 151 and covariates identified a priori as potential confounding variables associated with both antibody titer 152 and odds of infection (full adjustment). The following covariates were included in fully adjusted models: 153 vaccination status, gender, age category (18-49, 50-64, ≥65 years), frailty score, and Charlson 154 comorbidity index category (0, 1, 2, ≥3). 155
All statistical analyses were performed using SAS (release 9.3; SAS Institute); figures were prepared 156 using R software (version 3.1.0). A P-value of <.05 indicated statistical significance. 157
RESULTS 158
During the 2014-2015 influenza season, 624 patients with acute respiratory illness were enrolled in the 159 VE study. Of these, 341 were enrolled at the University of Michigan Hospital and serum specimens were 160 retrieved for 315 (92%) of these patients. Tables 1 and 2 ). However, subjects with specimens retrieved from the Henry 7 Ford Hospital during the 2015-2016 season (52%) were more likely to be white (28% vs 13%, P=0.03) and 166 have higher Charlson comorbidity index (3+: 53% vs 38%, P=0.02) compared to those subjects for whom 167 specimens were unable to be retrieved (Supplemental Table 2 ). The characteristics of the subjects with 168 specimens retrieved during each season are presented in Tables 1 and 2, respectively.  169 Blood specimens were collected 0-10 days after illness onset; specimens were collected within 3 days of 170 illness from 65% of patients and within 6 days from 89%. Overall, GMTs did not significantly vary by the 171 time of specimen collection. The effect of time of specimen relative to illness onset on antibody titers 172 was further explored among influenza positive cases, and we did not observe an association between 173 timing of blood collection and HAI or NAI antibody titers against viruses similar to those that circulated 174 in each season ( Figure 1 ). In addition, the variance of the measured titers did not appear to be 175 associated with the timing of blood collection. This supports our assumption that measured antibody 176 titers reflect pre-infection susceptibility rather than a de novo response to infection. Among influenza 177 negative subjects, we also did not observe an association between day of illness onset and HAI or NAI 178 antibody titers (or their variance) against viruses similar to those that circulated in each season 179 (Supplemental Figure 1 ). This suggests that a there was not substantial misclassification of case-control 180 status based on calendar time of enrollment. 181
Among subjects enrolled in the 2014-2015 season, the overall HAI GMT was 38.8 (95% CI: 33.5, 44.8) 182
against the A/Texas (H3N2) 3C.1 vaccine strain, and particularly low (10.4, 95% CI: 9.2, 11.8) against the 183 A/Hong Kong (H3N2) 3C.2a that more closely resembled the circulating strain. The overall NAI GMT was 184 124.5 (95% CI: 109.3, 141.9) against the A/Texas (H3N2) vaccine strain (Table 1 ). NAI titers against 185 A/Texas (H3N2) increased with age (P = 0.02), and HAI titers against A/Hong Kong (H3N2) were higher 186 among individuals with higher frailty scores (P=0.04). For all viruses tested, vaccinated individuals had 187 significantly higher A(H3N2) HAI and NAI titers than unvaccinated individuals (P<0.001) in these serum 188 specimens. GMTs were higher in those not infected than those who were, but none of the differences 189 were statistically significant (Table 1) . 190
For the following year, the overall HAI and NAI GMTs against the A/California (H1N1)pdm09 vaccine 191 strain were 55.9 (95% CI: 47.9, 65.3) and 50.5 (95% CI: 42.5, 59.9), respectively ( Table 2) (Table 3 ). For A/Hong Kong, a 2-fold increase in HAI titer was estimated to 207 reduce odds of infection by 14% (95% CI: -19%, 48%), but this was not statistically significant. 208
In contrast, the proportion infected by A(H1N1)pdm09 in 2015-2016 appeared to decrease with 209 increasing HAI and NAI titers against influenza A(H1N1)pdm09 (Figure 3 ). Consistent with this both HAI 210 and NAI titers were significantly associated with reduced odds of infection in unadjusted and partially adjusted logistic regression models (Table 3 ). In fully adjusted multivariable logistic regression models, a 212 2-fold increase in HAI titer was associated with a 22% (95% CI: 7%, 35%) reduction in the odds of 213 influenza A(H1N1)pdm09 infection, and a 2-fold increase in NAI titer was estimated to reduce the odds 214 of infection by 12% (95% CI: -3%, 25%; Table 3 ); however, only the association between HAI titer and 215 odds of influenza A(H1N1)pdm09 infection remained statistically significant after full covariate 216 adjustment. 217
We compared HAI and NAI antibody titers by two-year vaccination status in both study seasons ( Figure  218   4 ). In each season and for each antigen, the group with the lowest titers were those unvaccinated in 219 both seasons. In both seasons, HAI and NAI titers against all antigens did not significantly differ 220 comparing those vaccinated only in the current season and those vaccinated in two consecutive 221 seasons. 222
DISCUSSION 223
Studies of influenza VE are now conducted annually in many parts of the word, mainly in ambulatory 224 populations using the test negative design [4] [5] [6] . By virtue of recruiting in the ambulatory care setting it 225 is difficult to collect adequate blood specimens from the numbers of subjects needed to evaluate 226 serologic correlates of protection. In hospitalized individuals, with little alteration in routine practice, it 227 is often possible to obtain residual serum specimens collected for clinical purposes. The question, in the 228 case of study enrollment at the time of hospitalization, is whether antibodies measured in these serum 229 specimens are indicative of pre-infection levels of susceptibility. The current results indicate that this is 230 possible, particularly because specimens were collected shortly after acute respiratory illness onset for 231 most patients. The fact that antibody titers were significantly higher among those who were vaccinated 232 is also consistent with expectations for pre-infection antibody measurements. 233
The usefulness of these specimens is further indicated by the findings in the two influenza seasons 234 which were divergent, but consistent with vaccine effectiveness estimates. Influenza A(H3N2) viruses 235 which were antigenically mismatched to the A/Texas (H3N2) virus included in the vaccine circulated 236 widely during the 2014-2015 influenza season [19, 20] . Consistent with this mismatch, studies carried out 237 in the outpatient setting observed an absence of VE in preventing infection by drifted A(H3N2) viruses 238 [9] . In this study, HAI antibody titer against A/Texas (H3N2) did not correlate with protection against 239 infection as expected. In contrast, there were no infections identified in the few individuals with titers 240 ≥40 against A/Hong Kong (H3N2), which belongs to the 3C.2a genetic group that includes the majority of 241 2014-2015 circulating A(H3N2) viruses. Vaccinated individuals had higher titers against both viruses than 242 unvaccinated individuals, and unlike studies carried out in ambulatory care and household settings, we 243 found that the A/Texas (H3N2) containing vaccine was 43% effective in this hospitalized population [13] . 244
The 2015-2016 influenza season was characterized by circulating influenza A(H1N1) viruses that were 245 considered to be antigenically similar to the A/California (H1N1)pdm09 vaccine strain by standard HAI 246 assays using ferret anti-sera [21] . Outpatient and inpatient based VE studies consistently estimated 247 moderate VE in this season [17] . Consistent with this, we observed higher titers among vaccinated 248 individuals and HAI antibody against A/California (H1N1)pdm09 was associated with protection from 249 influenza A(H1N1)pdm09 infection in the 2015-2016 season. 250
Our group and others have previously demonstrated that NAI antibody is a correlate of protection 251 against influenza infection independent of HAI antibody [22, 23] . Here higher NAI titers were associated 252 with reduced odds of infection only in the 2015-2016 season, but this effect was not statistically 253 significant in fully adjusted models potentially reflecting low sample size. Although NA content is not 254 standardized in influenza vaccines, it has been previously demonstrated that a substantial proportion of 255 vaccinated individuals produce NA directed antibody in response to vaccination [22, 24] . Given the 256 potential for NA antibody to contribute to protection, more systematic monitoring of the antigenic 257 properties of NA in circulating viruses, as is done with HA, is needed to inform appropriate targets for 258 this relatively new assay. This will be particularly important as new approaches for vaccine production 259 that will give broader protection are examined [12] . 260
The primary limitation of this study is that only single serum specimens collected during acute illness 261 were available. Although, our results support the assumption that antibody measured in these 262 specimens are representative of levels present prior to infection, this cannot be definitively determined 263 without paired pre-infection specimens. One recent study of antibody kinetics in patients hospitalized 264 found that HAI titers rose rapidly after infection with >80% having HAI titers ≥40 within two weeks [25] ; 265 in our study, 89% of patients had specimens collected ≤6 days after illness onset. Similarly, vaccinated 266 subjects had higher HAI and NAI titers against all measured influenza antigens suggesting that these 267 antibodies were produced in response to influenza vaccination. However, because pre-vaccination 268 serum specimens were unavailable we cannot determine how much current season vaccine contributed 269 to the development of these antibodies. 270
Because enrollment in this study was cross-sectional, it is possible that individuals defined as influenza 271 negative controls could have been infected prior to or after enrollment. This misclassification would be 272 expected to bias estimated associations between antibody titer and odds of infection toward the null. If 273 this bias were present, controls enrolled later in the season would be expected to have a higher 274 probability of being infected prior to the illness for which they were enrolled, and therefore, higher 275 antibody titers than those enrolled earlier in the season. We did not observe such a relationship, and 276 therefore, would expect any misclassification of infection status to be minimal. Because this study was 277 carried out in only two hospitals in Southeast Michigan, the generalizability of the results to other 278 populations is unclear; however, the results are generally consistent with larger, national studies of 279 influenza vaccine effectiveness. The results of this study should also be interpreted in the context of 280 limited sample size. 281
The case-test negative design has allowed for efficient annual estimation of the effectiveness of 282 influenza vaccines. These studies have been critical in informing public health policy by identifying issues 283 with current influenza vaccines such as the poor performance of live-attenuated influenza vaccines in 284 recent years [17, 26] . More generally, these studies have consistently reported low VE against influenza 285 A(H3N2) viruses even in seasons when the hemagglutinins of vaccine strain viruses are considered well 286 matched to those that circulate [7] . Pairing these studies with immunologic evaluations, though difficult, 287 is currently a major unmet need for interpreting annual VE estimates. The results of this study support 288 the utility of using serum specimens collected during acute illness to assess correlates of protection 289 against influenza infection to support hospital-based studies of influenza VE. Implementation of similar 290 studies more broadly would provide an opportunity to understand the successes and shortcomings of 291 current influenza vaccines. 292 13 Table 1 . Geometric mean antibody titers among adults hospitalized for acute respiratory illness during the 2014-2015 influenza season by subject characteristics.
Abbreviations: 95% CI, 95% confidence interval; GMT, geometric mean titer; HAI, hemagglutination-inhibition; NAI, neuraminidase-inhibition. a P-values are calculated from unbalanced ANOVA F-test on the original log titers. b 
Supplementary Materials
Frailty Score
During the enrollment interview, each participant was asked five questions comprising a frailty short interview based on the components of the frailty phenotype defined by Fried et al. [27] . Participants were asked the following questions:
"In the last year, before this current illness, have you lost more than 10 pounds unintentionally (i.e., not due to dieting or exercise)?" [YES;NO]; adapted from [27] .
"In the last month, before this current illness, have you had too little energy to do the things you wanted to do?" [YES;NO]; adapted from [28] .
"Before this current illness, how difficult was it for you to lift or carry something as heavy as 10 pounds, such as a full bag of groceries, by yourself, and without using any special equipment?" [NO DIFFICULTY; A LITTLE…; SOME…; A LOT…; UNABLE TO DO]; adapted from [29] .
"Before this current illness, did you have difficulty walking 100 yards (around the size of a football field) because of a health problem?" [NO DIFFICULTY; A LITTLE…; SOME…; A LOT…; UNABLE TO DO];
adapted from [28] .
"Before this current illness, how often did you engage in activities that require a low or moderate level of energy such as gardening, cleaning the car, or going for a walk?" [>ONCE PER WEEK; ONCE PER WEEK; 1-3 TIMES PER MONTH; HARDLY EVER/NEVER]; adapted from [28] .
Responses to the last three questions were recoded as dichotomous variables with at least some difficulty or engaging in physical less than once per week indicating positive responses indicative of vaccine. Serum specimens were heat inactivated, and serial 2-fold dilutions (with an initial dilution of 1:10) were incubated with virus and then added to 96-well microtiter plates coated with fetuin in duplicate. A 25mM MES buffer is used throughout the assay as diluent and for plate washing. A final solution of 20mM CaCl2 and 1% BSA are added to the diluents with a pH of 6.5. Following incubation, peroxidase-labeled peanut agglutinin (the lectin) and, later, peroxidase substrate were added to detect enzymatic cleavage of fetuin by viral NA, and the reaction optical density was measured with a microplate reader. The percentage inhibition of NA enzymatic activity at each serum dilution was calculated by comparison with values from virus control wells (virus but no serum); endpoint NAI titers were calculated as the reciprocal of the highest dilution with at least 50% inhibition. 
